Multi‐omics analysis identified IVD, CYFIP1, and ADD2 as autoantibody biomarkers for distinguishing AD from controls,185 biomarkers (FBP1, FBP2, RHOH, JPH2, ERAp2, and SCLT1) distinct from AD patients with APOE2 and APOE4,186 ABCA1, CPT1A, adiponectin, and NGAL to be associated with AD pathology,183 and 14‐3‐3 zeta/delta and clusterin associated with AD and cognitive decline.187. This evidence concerns the gene ERAP2 and Alzheimer disease.